Skip to Content
Merck
  • Synthesis, biological evaluation, and docking studies of gigantol analogs as calmodulin inhibitors.

Synthesis, biological evaluation, and docking studies of gigantol analogs as calmodulin inhibitors.

European journal of medicinal chemistry (2011-04-26)
Adelfo Reyes-Ramírez, Martha Leyte-Lugo, Mario Figueroa, Trinidad Serrano-Alba, Martín González-Andrade, Rachel Mata
ABSTRACT

Several analogs of gigantol (1) were synthesized to evaluate their effect on the complexes Ca(2+)-calmodulin (CaM) and Ca(2+)-CaM-CaM sensitive phosphodiesterase 1 (PDE1). The compounds belong to four structural groups including, 1,2-diphenylethanes (2-11), diphenylmethanes (13-15), 1,3-diphenylpropenones (16-18), and 1,3-diphenylpropanes (20-22). In vitro enzymatic studies showed that all compounds except 11 inhibited the complex Ca(2+)-CaM-PDE1 with IC(50) values ranging from 9 to 146 μM. On the other hand, all analogs but 11, 12 and 15 quenched the extrinsic fluorescence of the CaM biosensor hCaM-M124C-mBBr to different extent, then revealing different affinities to CaM; their affinity constants (K(m)) values were in the range of 3-80 μM. Molecular modeling studies indicated that all these compounds bound to CaM at the same site that the classical inhibitors trifluoperazine (TFP) and chlorpromazine (CPZ). Some of these analogs could be worthy candidates for developing new anti-tumor, local anesthetics, antidepressants, antipsychotic, or smooth muscle relaxant drugs, with anti-CaM properties due to their good affinity to CaM and the straightforwardness of their synthesis. In addition they could be valuable tools for the study of Ca(2+)-CaM functions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diphenylmethane, 99%
Sigma-Aldrich
Bibenzyl, ReagentPlus®, 99%